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in such therapeutic protocols need to be monitored very carefully not 
only for treatment outcome, but also for treatment-related morbidity. 
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Improvements in survival after a primary cancer diagnosis mean that 
the risk of radiation induced second cancer and cardiovascular disease 
become important survivorship issues. 
As well as individual patient factors, risk of late effects is known to be 
related to the dose distribution, volume irradiated, total dose and 
dose rate. Using early prostate cancer and breast cancer as clinical 
examples this lecture will review risks from registry data and 
institutional series with particular emphasis on whether specific 
techniques are associated with lower risks. The physical dose 
distributions delivered to OAR with commonly used radiation 
techniques will be demonstrated with a comparison of differences in 
intergral dose, defined as mean dose times OAR volume. 
In prostate and breast cancer survivors, do brachytherapy techniques 
improve outcome with respect to radiation induced second cancers 
and cardiovascular disease? 
Can risk prediction models be developed that allow customised follow 
up and evidence based interventions to reduce the risk of late side 
effects?  
 
  
